Amgen Names Anna Richo Senior Vice President of Worldwide Compliance

THOUSAND OAKS, Calif.--(Business Wire)--
Amgen (NASDAQ:AMGN) today announced the appointment of Anna S.
Richo as senior vice president, Worldwide Compliance. Richo will head
the organization responsible for Amgen's corporate compliance and
business ethics programs. She will report to Amgen Chairman and Chief
Executive Officer Kevin Sharer.

Richo, 47, joined Amgen in 2003 and was most recently vice
president, Law, responsible for worldwide management of all corporate
litigation and law department operations. Prior to Amgen, she spent 12
years at Baxter Healthcare Corporation in roles of increasing
responsibility in law, including vice president, Law, for Baxter's
BioScience Division. Also, for more than five years Richo served on
the Board of Directors of Cytyc Corporation and was a member of the
Audit and Finance Committees.

"As the compliance demands on biopharmaceutical companies are
increasing, we want to ensure Amgen's continued excellent performance
in this area in the interests of patients and all our stakeholders,"
said Sharer.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative
human therapeutics. A biotechnology pioneer since 1980, Amgen was one
of the first companies to realize the new science's promise by
bringing safe and effective medicines from lab, to manufacturing
plant, to patient. Amgen therapeutics have changed the practice of
medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our
pioneering science and our vital medicines, visit www.amgen.com.

Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Cory Rivera, 805-447-1060 (investors)

Copyright Business Wire 2008